|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
17 October 2012 |
|
Main ID: |
NCT00139906 |
|
Date of registration:
|
30/08/2005 |
|
Primary sponsor: |
|
|
Public title:
|
Twice Daily Titration Study of Bifeprunox in Subjects With Schizophrenia
|
|
Scientific title:
|
A Randomized, Double-Blind, Placebo-Controlled, Twice Daily Titration Study of the Safety and Tolerability of Bifeprunox in Subjects With Schizophrenia |
|
Date of first enrolment:
|
August 2005 |
|
Target sample size:
|
|
|
Recruitment status: |
Completed |
|
URL:
|
http://clinicaltrials.gov/show/NCT00139906 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment
|
|
|
Countries of recruitment
|
|
United States
| | | | | | | |
|
Contacts
|
|
Name:
|
Global Clinical Director Solvay |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Solvay Pharmaceuticals |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Subjects who have current diagnosis of Schizophrenia or Schizoaffective disorder
- Body weight of 100-250 lbs
- Male or females
- 18-55 years of age
Exclusion Criteria:
- Subjects who are acutely psychotic
- Subjects with current Axis I primary psychiatric diagnosis other than schizophrenia,
at significant risk of suicide
Age minimum:
18 Years
Age maximum:
55 Years
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Schizoaffective Disorder
|
|
Schizophrenia
|
|
Intervention(s)
|
|
Drug: Bifeprunox
|
|
Secondary ID(s)
|
|
S154.2.016
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|